Medtronic PLC $MDT Shares Sold by Rathbones Group PLC

Rathbones Group PLC trimmed its holdings in shares of Medtronic PLC (NYSE:MDT) by 19.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,746 shares of the medical technology company’s stock after selling 12,766 shares during the period. Rathbones Group PLC’s holdings in Medtronic were worth $5,067,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of MDT. Delos Wealth Advisors LLC acquired a new stake in Medtronic during the 2nd quarter valued at approximately $27,000. Corundum Trust Company INC acquired a new stake in Medtronic during the 3rd quarter valued at approximately $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic during the 4th quarter valued at approximately $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic during the 3rd quarter valued at approximately $29,000. Finally, Board of the Pension Protection Fund acquired a new stake in Medtronic during the 4th quarter valued at approximately $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MDT has been the subject of several research reports. Sanford C. Bernstein lifted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Wells Fargo & Company initiated coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Robert W. Baird decreased their price objective on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. UBS Group reaffirmed a “neutral” rating and set a $104.00 target price on shares of Medtronic in a report on Wednesday, February 4th. Finally, Mizuho raised shares of Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $109.85.

Medtronic Price Performance

NYSE:MDT opened at $86.27 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The firm has a market cap of $110.77 billion, a price-to-earnings ratio of 24.03, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. The company has a 50 day moving average price of $94.18 and a 200-day moving average price of $96.19. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s payout ratio is 79.11%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).